Navigation Links
Jefferson scientists find protein potential drug target for treatment-resistant prostate cancer

(PHILADELPHIA) Scientists at Jeffersons Kimmel Cancer Center in Philadelphia have found that a signaling protein that is key to prostate cancer cell growth is turned on in nearly all recurrent prostate cancers that are resistant to hormone therapy. If the findings hold up, the protein, called Stat5, may be a specific drug target against an extremely difficult-to-treat cancer.

In addition, the researchers, led by Marja Nevalainen, M.D., Ph.D., associate professor of Cancer Biology at Jefferson Medical College of Thomas Jefferson University, also showed that the convergence of two biological pathways could be responsible for making such hormone-resistant prostate cancers especially dangerous. They have found that a synergy between Stat5 and hormone receptors in recurrent prostate cancer cells helps each maintain its activity. Dr. Nevalainen and her co-workers report their findings January 1, 2008 in the journal Cancer Research.

These findings validate Stat5 as a potential drug target in prostate cancer, and in particular, in a form of prostate cancer for which there are no effective therapies, Dr. Nevalainen says.

Men with primary prostate cancer usually have either surgery or radiation, whereas subsequent disease is frequently treated by hormone therapy. But if the cancer recurs again, years later, it can be more aggressive and typically fails to respond to hormone treatment. In previous work, the researchers showed that when Stat5 is turned on in primary prostate cancer, men are more likely to have recurrent disease.

In the current study, the team examined human prostate cancer cells of 198 patients with prostate cancer recurrence. They found that Stat5 was active in 74 percent of all recurrent prostate cancers. Of these patients, 127 had been treated with androgen deprivation therapy. The researchers found Stat5 was active in 95 percent of these hormone resistant tumors, meaning it was more likely to be active if the patient had been treated with hormone deprivation therapy.

Dr. Nevalainen shows that Stat5 interacts with the androgen receptors and keeps them transcriptionally active. Next, the scientists would like to conduct tests in animal models to see if this synergy promotes androgen-independent prostate tumor growth, and whether or not Stat5 synergizes with androgen receptors activated by adrenal androgens, which are present in the absence of testicular androgens during the hormone therapy of prostate cancer in patients.


Contact: Steve Benowitz
Thomas Jefferson University

Related medicine news :

1. Jefferson specialists studying innovative surgery for effectively treating sleep apnea
2. Jefferson immunology researchers halt lethal rabies infection in brain
3. Jefferson radiation oncologists use real-time system to plant seeds against cancer
4. Jefferson researchers find personalized interventions key to improving colon cancer screening rates
5. Jefferson researchers uncover new evidence of prolactins possible role in breast cancer
6. MicroRNAs may be key to HIVs ability to hide, evade drugs, Jefferson scientists find
7. Jefferson scientists find protein may be key in developing deadly form of pancreatic cancer
8. Jefferson oncologists show focused radiation is effective as surgery against nerve tumor
9. Jefferson researchers find stem cells in degenerating spinal discs, potential for repair
10. Jefferson researchers show chemotherapy and radiation together extend lung cancer patients lives
11. Jefferson neuroscientists show anti-inflammation molecule helps fight MS-like disease
Post Your Comments:
(Date:11/24/2015)... FL (PRWEB) , ... November 24, 2015 , ... In ... a growing epidemic as deaths from prescription opioids in the United States grew 400 ... cocaine. In 2013 alone, opioids were involved in 37 percent of all fatal drug ...
(Date:11/24/2015)... ... , ... Serenity Point Rehabilitation, a holistic treatment center for substance abuse located ... the staff members at their recovery center. The videos highlight some of the various ... the things that make their recovery program so unique. , “Making the decision to ...
(Date:11/24/2015)... ... November 24, 2015 , ... Chiropractic student Katie Benson received ... in Overland Park, Kansas. Benson, a fifth-trimester student in the university’s College of ... on October 16. , “Katie is very excited and greatly appreciative to receive ...
(Date:11/24/2015)... ... November 24, 2015 , ... Autism Speaks, the world’s leading autism science ... social media and the generosity of people around the world. On December 1, supporters ... to give – and share the personal stories behind those gifts. , Just ...
(Date:11/24/2015)... IL (PRWEB) , ... November 24, 2015 , ... ... and engineer of patented products, announces Fragrance by Marcelle, a cosmetic invention which ... The Perfume & Fragrance Manufacturing Market in the US is worth $3 billion ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... st  Scientific Assembly and Annual Meeting of the Radiological ... in Chicago on Nov-29 th through ... st  Scientific Assembly and Annual Meeting of the Radiological Society of ... Chicago on Nov-29 th through Dec-4 th ... will present its revolutionary whole body CZT digital SPECT/CT solution at ...
(Date:11/24/2015)... , Nov. 24, 2015  Family Rentals, ... recently announced the launch of their newly designed, ... --> --> ... --> --> Now, renting ... travel and vacation, just got a whole lot ...
(Date:11/24/2015)... LONDON , November 24, 2015 ... PCSK9 Inhibitors, CETP Inhibitors, MTTP Inhibitors, ApoB Inhibitors and ... areas are going to grow at the fastest rates? ... to 2025, assessing data, trends, opportunities and prospects there. ... graphs. Discover the most lucrative areas in the industry ...
Breaking Medicine Technology: